Weekly review: Deli meats linked to listeria outbreak, roflumilast foam 0.3% sNDA submission and more
Get caught up with our journal! Review some of the top stories from the Contemporary Pediatrics website over the last week, and catch up on anything you may have missed.
Thank you for visiting the Contemporary Pediatrics® website. Take a look at some of our top stories from last week (Monday, July 22, to Friday, July 26, 2024), and click on each link to read and watch anything you may have missed.
1.) Sliced meats at delis linked to listeria outbreak across 12 states
According to data from the Centers for Disease Control and Prevention (CDC), as of July 19, 2023, a Listeria outbreak linked to meats sliced at delis has resulted in 2 deaths and 28 hospitalizations across 12 states. A CDC investigation is underway with no active recall in place, as investigators continue to collect information.
2.) Roflumilast foam 0.3% sNDA submitted to treat scalp and body psoriasis in patients 12 years and up
Another potential indication for Arcutis' roflumilast (Zoryve) lineup will now be reviewed by the FDA after the company submitted a supplemental New Drug Application (sNDA) for roflumilast foam 0.3% to treat scalp and body psoriasis in adults and adolescents aged 12 years and older.
Click here for full submission details.
3.) Obesity in the adolescent and young adult populations
The best available evidence-based practice for prescribing GLP-1 drugs to the pediatric populations, is addressed in the 2023 American Academy of Pediatrics (AAP) first clinical practice guideline titled, “Clinical practice guideline for the evaluation and treatment of children and adolescents with obesity.”
4.) Comparison of teen- and parent-reported estimates of social and emotional support, 2021 to 2022
The investigative team noted that teenagers with emotional and social support are better off to handle stressors such as biological and social transition, and are less likely to experience a variety of adverse physical and mental health outcomes.
Click here for the full article.
5.) Merck's investigational RSV monoclonal antibody clesrovimab demonstrates positive results
Positive, topline safety and efficacy data has been reported for clesrovimab (MK-1654; Merck), an investigational prophylactic monoclonal antibody created to protect infants from respiratory syncytial virus (RSV) disease, according to a press release from Merck. The positive data is from the phase 2b/3 MK-1654-004 (NCT04767373) clinical trial.
